$CLPT
ClearPoint Neuro, Inc. Stock $clpt

$clpt Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000128555022000014 Filed on May 11, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$5.200M	$5.031M	$4.282M
YoY Change	52.36%	24.84%	15.11%
Cost Of Revenue	$1.943M	$1.785M	$993.0K
YoY Change	70.59%	26.06%	-30.56%
Gross Profit	$3.257M	$3.246M	$3.289M
YoY Change	43.23%	24.18%	44.25%
Gross Profit Margin	62.63%	64.52%	76.81%
Selling, General & Admin	$5.177M	$2.732M	$4.537M
YoY Change	44.93%	64.88%	66.8%
% of Gross Profit	158.95%	84.17%	137.94%
Research & Development	$2.284M	$2.533M	$2.734M
YoY Change	8.3%	62.06%	49.4%
% of Gross Profit	70.13%	78.03%	83.13%
Depreciation & Amortization	$101.0K	$86.00K	$46.00K
YoY Change	140.48%	473.33%	-71.25%
% of Gross Profit	3.1%	2.65%	1.4%
Operating Expenses	$7.461M	$5.265M	$7.271M
YoY Change	31.33%	63.51%	59.8%
Operating Profit	-$4.204M	-$3.864M	-$3.982M
YoY Change	23.39%	77.17%	75.42%
Interest Expense	-$91.00K	$106.0K	-$164.0K
YoY Change	-62.08%	-68.07%	-18.0%
% of Operating Profit
Other Income/Expense, Net	-$8.000K	$11.00K	-$3.000K
YoY Change	-91.67%	-144.0%	-100.34%
Pretax Income	-$4.303M	-$3.959M	-$4.149M
YoY Change	14.96%	55.87%	162.59%
Income Tax
% Of Pretax Income
Net Earnings	-$4.303M	-$3.959M	-$4.149M
YoY Change	14.96%	55.99%	162.59%
Net Earnings / Revenue	-82.75%	-78.69%	-96.89%
Basic Earnings Per Share	-$0.18	-$0.17
Diluted Earnings Per Share	-$179.4K	-$0.17	-$194.8K
COMMON SHARES
Basic Shares Outstanding	23.72M shares	23.68M shares
Diluted Shares Outstanding	23.99M shares	23.68M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$45.14M	$49.66M	$54.11M
YoY Change	-26.64%	-23.44%	169.2%
Cash & Equivalents	$23.52M	$49.66M	$54.11M
Short-Term Investments	$21.61M
Other Short-Term Assets	$1.517M	$380.0K	$508.0K
YoY Change	51.25%	52.0%	111.67%
Inventory	$6.639M	$5.732M	$4.938M
Prepaid Expenses
Receivables	$3.348M	$2.243M	$2.337M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$56.64M	$58.01M	$61.89M
YoY Change	-17.32%	-17.57%	143.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.681M	$709.0K	$539.0K
YoY Change	-5.53%	-75.64%	68.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$598.0K	$94.00K	$125.0K
YoY Change	-10.75%	-85.54%	111.86%
Total Long-Term Assets	$3.599M	$3.755M	$3.689M
YoY Change	-5.71%	-3.22%	-9.05%
TOTAL ASSETS
Total Short-Term Assets	$56.64M	$58.01M	$61.89M
Total Long-Term Assets	$3.599M	$3.755M	$3.689M
Total Assets	$60.24M	$61.77M	$65.58M
YoY Change	-16.71%	-16.82%	122.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.592M	$965.0K	$427.0K
YoY Change	27.16%	32.19%	42.33%
Accrued Expenses	$3.216M	$2.467M	$3.648M
YoY Change	16.31%	30.53%	55.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.483M	$3.973M	$4.753M
YoY Change	25.04%	27.34%	48.53%
LONG-TERM LIABILITIES
Long-Term Debt	$9.865M	$9.851M	$9.838M
YoY Change	-43.64%	-59.82%	-53.77%
Other Long-Term Liabilities	$2.072M	$2.214M	$2.203M
YoY Change	-16.15%	-16.45%	-17.18%
Total Long-Term Liabilities	$11.94M	$12.07M	$12.04M
YoY Change	-40.24%	-55.59%	-49.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.483M	$3.973M	$4.753M
Total Long-Term Liabilities	$11.94M	$12.07M	$12.04M
Total Liabilities	$17.42M	$16.04M	$16.79M
YoY Change	-28.49%	-47.03%	-38.12%
SHAREHOLDERS EQUITY
Retained Earnings		-$137.9M	-$133.9M
YoY Change			12.06%
Common Stock		$183.6M	$182.7M
YoY Change			49.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$42.82M	$45.73M	$48.79M
YoY Change
Total Liabilities & Shareholders Equity	$60.24M	$61.77M	$65.58M
YoY Change	-16.71%	-16.82%	122.17%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$4.303M	-$3.959M	-$4.149M
YoY Change	14.96%	55.99%	162.59%
Depreciation, Depletion And Amortization	$101.0K	$86.00K	$46.00K
YoY Change	140.48%	473.33%	-71.25%
Cash From Operating Activities	-$4.981M	-$4.300M	-$3.552M
YoY Change	33.93%	101.78%	48.0%
INVESTING ACTIVITIES
Capital Expenditures	-$76.00K	$69.00K	-$38.00K
YoY Change	-317.14%	72.5%	-5.0%
Acquisitions
YoY Change
Other Investing Activities	-$21.59M
YoY Change
Cash From Investing Activities	-$21.67M	-$185.0K	-$38.00K
YoY Change	-62002.86%	362.5%	-5.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	513.0K	$3.000K	48.00K
YoY Change	46.99%	-99.99%	-99.39%
NET CHANGE
Cash From Operating Activities	-4.981M	-$4.300M	-3.552M
Cash From Investing Activities	-21.67M	-$185.0K	-38.00K
Cash From Financing Activities	513.0K	$3.000K	48.00K
Net Change In Cash	-26.13M	-$4.451M	-3.542M
YoY Change	683.63%	-109.94%	-165.23%
FREE CASH FLOW
Cash From Operating Activities	-$4.981M	-$4.300M	-$3.552M
Capital Expenditures	-$76.00K	$69.00K	-$38.00K
Free Cash Flow	-$4.905M	-$4.369M	-$3.514M
YoY Change	30.66%	101.24%	48.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Entity File Number EntityFileNumber	001-34822
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001285550
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	ClearPoint Neuro, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2394628
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	120 S. Sierra Ave.
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Solana Beach
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92075
CY2022Q1	dei	City Area Code CityAreaCode	(888)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	287-9109
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	CLPT
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23717281	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49658000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54109000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2243000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2337000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	5732000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4938000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	380000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	508000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	58013000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	61892000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	709000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2116000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2241000	USD
CY2022Q1	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	484000	USD
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	678000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3973000	USD
CY2021Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	519000	USD
CY2022Q1	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	352000	USD
CY2021Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	265000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	94000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	125000	USD
CY2022Q1	us-gaap	Assets Assets	61768000	USD
CY2021Q4	us-gaap	Assets Assets	65581000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	965000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	427000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1344000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2604000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	602000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	537000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	521000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	507000	USD
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	541000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4753000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1806000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1939000	USD
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	408000	USD
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	264000	USD
CY2022Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	9851000	USD
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	9838000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	16038000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	16794000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23708118	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23708118	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23665991	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23665991	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	237000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	237000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	183384000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45730000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48787000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61768000	USD
CY2021Q1	us-gaap	Revenues Revenues	4030000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65581000	USD
CY2022Q1	us-gaap	Revenues Revenues	5031000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	1785000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	1416000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	3246000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	182482000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137891000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133932000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	2614000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2533000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1563000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1845000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	332000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1575000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2732000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1657000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3864000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2181000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	106000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3959000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2538000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23682442	shares
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-30000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2377000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23682442	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18852828	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18852828	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48787000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	899000	USD
CY2022Q1	clpt	Warrant And Option Exercises Cash And Cashless WarrantAndOptionExercisesCashAndCashless	3000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3959000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	45730000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46785000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	320000	USD
CY2021Q1	clpt	Warrant And Option Exercises Cash And Cashless WarrantAndOptionExercisesCashAndCashless	145000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2538000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	43982000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3959000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2538000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	899000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	320000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-128000	USD
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2021Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	133000	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	94000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-61000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	86000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	35000	USD
CY2022Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	133000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-155000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	126000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	880000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-47000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-692000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-54000	USD
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-128000	USD
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-94000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	41000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4269000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2131000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40000	USD
CY2022Q1	clpt	Acquisition Of Licensing Rights AcquisitionOfLicensingRights	116000	USD
CY2021Q1	clpt	Acquisition Of Licensing Rights AcquisitionOfLicensingRights	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-185000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46785000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	44759000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54109000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20099000	USD
CY2022Q1	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	3000	USD
CY2021Q1	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	145000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46930000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4451000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46800000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49658000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64858000	USD
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	100000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	214000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000	USD
CY2022Q1	clpt	Net Transfers Of Reusable Components From Loaned Systems NetTransfersOfReusableComponentsFromLoanedSystems	100000	USD
CY2021Q1	clpt	Net Transfers Of Reusable Components From Loaned Systems NetTransfersOfReusableComponentsFromLoanedSystems	100000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-3100000	USD
CY2022Q1	clpt	Number Of Companies NumberOfCompanies	45	company
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137900000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4300000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12700000	USD
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2127660	shares
CY2021Q4	clpt	Inventory Software Licenses InventorySoftwareLicenses	210000	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration Risks and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company holds substantially all its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At March 31, 2022, the Company had approximately $44.0 million in bank balances that were in excess of the insured limits.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022, there were two customers (one of which is a related party as discussed below) whose accounts receivable balances represented 13% and 11% of accounts receivable at that date. At December 31, 2021, one customer accounted for 15% of accounts receivable at that date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One pharmaceutical customer, a related party who is a stockholder, a noteholder, and who has a representative on the Company's Board of Directors (see Note 5), for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 19% and 17% of total sales in the three-month periods ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to granting credit, the Company performs credit evaluations of its customers’ financial condition, and generally does not require collateral from its customers. The Company will provide an allowance for doubtful accounts when collections become doubtful. The allowance for doubtful accounts at March 31, 2022 and December 31, 2021 was $0.2 million and $0.3 million, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; dependence on third-party collaboration, license and joint development partners; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.</span></div>
CY2022Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	44000000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	200000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2021	clpt	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature1 AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature1	3100000	USD
CY2022Q1	us-gaap	Revenues Revenues	5031000	USD
CY2021Q1	us-gaap	Revenues Revenues	4030000	USD
CY2021Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	100000	USD
CY2022Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	100000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3620000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2718000	USD
CY2022Q1	clpt	Inventory Software Licenses InventorySoftwareLicenses	210000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1902000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2010000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	5732000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4938000	USD
CY2022Q1	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	484000	USD
CY2021Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	519000	USD
CY2022Q1	us-gaap	Inventory Gross InventoryGross	6216000	USD
CY2021Q4	us-gaap	Inventory Gross InventoryGross	5457000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	10000000	USD
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	149000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	9851000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	100000	USD
CY2022Q1	us-gaap	Lease Cost LeaseCost	100000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	899000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	320000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	900000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1350473	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.10
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.60
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	24933	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	37.68
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1324540	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.59
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7499000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	22918	shares
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	5071000	USD
CY2021Q4	clpt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	2.97
CY2022Q1	clpt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageExercisePrice	2.20
CY2022Q1	clpt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	2.98

Files In Submission

Name	View Source	Status
0001285550-22-000014-index-headers.html	Edgar Link	pending
0001285550-22-000014-index.html	Edgar Link	pending
0001285550-22-000014.txt	Edgar Link	pending
0001285550-22-000014-xbrl.zip	Edgar Link	pending
clpt-20220331.htm	Edgar Link	pending
clpt-20220331.xsd	Edgar Link	pending
clpt-20220331xex3111.htm	Edgar Link	pending
clpt-20220331xex3121.htm	Edgar Link	pending
clpt-20220331xex321.htm	Edgar Link	pending
clpt-20220331_cal.xml	Edgar Link	unprocessable
clpt-20220331_def.xml	Edgar Link	unprocessable
clpt-20220331_htm.xml	Edgar Link	completed
clpt-20220331_lab.xml	Edgar Link	unprocessable
clpt-20220331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLPT
ClearPoint Neuro, Inc. Stock $clpt

2022 Q2 Form 10-Q Financial Statement

#000128555022000014 Filed on May 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT ClearPoint Neuro, Inc. Stock $clpt

2022 Q2 Form 10-Q Financial Statement

#000128555022000014 Filed on May 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT
ClearPoint Neuro, Inc. Stock $clpt